This Company Is Using Enzymatic DNA Synthesis To Usher In The Next Generation Of Synthetic Biology Innovation

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 45 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 59%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Ansa Biotechnologies is turning DNA synthesis on its head by using enzymatic synthesis to produce gene-length oligos and finally unlock complex, elegant synthetic biology solutions in human health, agriculture, and so much more.

Ansa Biotechnologies, Inc.

Contrasting his experience with what he knew about computer science, Lin-Arlow remembers thinking that “If it took a month to recompile code, we wouldn't have all this tech that we now enjoy and that’s changed the world — but that’s what it feels like in many cases when you’re engineering cells.

Now, just five years after reporting that first 10-mer, Ansa has nearly met their goal of routinely providing 1000-mers to the market.In an important next step toward reaching that goal, Ansa launched theirlast month, which provides synthetic DNA constructs to a select group of partners.

Eventually, he says, Ansa will offer pooled oligos, asking me to imagine an array synthesizer that can make hundreds of thousands or even millions of very large gene-length oligos. It might seem like a pipe dream, but people are asking for it, says Lin-Arlow — and he plans to deliver.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 318. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Revolut CFO to depart company after two years, company saysInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »